SCHEMBL10069075

SCHEMBL10069075

Cc1cccc(/C=C/C2CCN(C(=O)CN3CCOCC3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 6/20 0.44
MAPK1 P28482 1/20 0.44
TSHR P16473 3/20 0.44
ALOX15 P16050 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 2/20 0.43
NAMPT P43490 2/20 0.42
TP53 P04637 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 1/20 0.41
GRIN2B Q13224 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
TDP1 Q9NUW8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14261845 0.89 TDP1 (0.51) MAPTALDH1A1NPC1RAB9ACYP2C19
SCHEMBL27637239 0.89 TSHR (0.48) MAPTKDM4EALDH1A1MAPK1TSHR
SCHEMBL14261804 0.88 NPC1 (0.46) MAPTKDM4EALDH1A1TSHRALOX15
SCHEMBL6012016 0.87 KMT2A (0.46) MAPTKDM4EALDH1A1MAPK1TSHR
SCHEMBL14261811 0.87 HTT (0.47) KDM4EALDH1A1TSHRALOX15HSD17B10
SCHEMBL14261820 0.87 MAOA (0.54) MAPTKDM4EALDH1A1TSHRALOX15
SCHEMBL6011799 0.87 TSHR (0.44) MAPTKDM4EALDH1A1TSHRALOX15
SCHEMBL14261824 0.87 HTT (0.47) KDM4EALDH1A1TSHRALOX15HSD17B10
SCHEMBL10069273 0.87 TSHR (0.44) MAPTKDM4EALDH1A1TSHRALOX15
SCHEMBL6009399 0.87 MAOA (0.54) MAPTKDM4EALDH1A1TSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1785415-B1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof ASTELLAS PHARMA INC. (JP) 2008-03-20 US disclosed
EP-1785415-A1 PIPERIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070898-A1 Piperidine Derivative or Pharmaceutically Acceptable Salt Thereof TRPV1, TRPA1, CACNA1D MAPT 2861/4885KDM4E 541/4885ALDH1A1 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.